A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF) - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction (VICTORIA)

Trial Profile

A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF) - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction (VICTORIA)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Vericiguat (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms VICTORIA
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 23 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top